Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002
暂无分享,去创建一个
[1] Ronald N. Jones,et al. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). , 2002, Diagnostic microbiology and infectious disease.
[2] D. Livermore,et al. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] A. Evangelista,et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. , 2002, International journal of antimicrobial agents.
[4] M. Pfaller,et al. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). , 2001, Diagnostic microbiology and infectious disease.
[5] Ronald N. Jones,et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] D. Livermore. Of Pseudomonas, porins, pumps and carbapenems. , 2001, The Journal of antimicrobial chemotherapy.
[7] J. Karlowsky,et al. Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance , 2001, Antimicrobial Agents and Chemotherapy.
[8] Albert Balows,et al. Manual of Clinical Microbiology, 7th ed. , 2000 .
[9] M. Pfaller,et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] M. Marsilio,et al. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Y. Carmeli,et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. , 1999, Archives of internal medicine.
[12] Y. Carmeli,et al. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] A. Levin,et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] Ronald N. Jones,et al. Bacterial Pathogens Isolated from Patients with Bloodstream Infection: Frequencies of Occurrence and Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) , 1998, Antimicrobial Agents and Chemotherapy.
[15] J. Chastre,et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .